Efficacy and safety of guselkumab, an anti-IL23 Monoclonal antibody, in patients with active psoriatic arthritis: A phase 2a, randomized, double-blind, placebo-controlled study

被引：0

作者：

Gottlieb, Alice ^{[1
]}

Deodhar, Atul ^{[2
]}

Boehncke, Wolf-Henning ^{[3
]}

Dong, Bin ^{[4
]}

Wang, Yuhua ^{[4
]}

Barchuk, William ^{[4
]}

Hsia, Elizabeth ^{[4
]}

机构：

[1] New York Med Coll, Dept Dermatol, Valhalla, NY 10595 USA

[2] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[3] Geneva Univ Hosp, Div Dermatol & Venereol, Geneva, Switzerland

[4] Janssen Res & Dev LLC, Raritan, NJ USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2017年 / 76卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

4454

引用

页码：AB111 / AB111

页数：1

共 50 条

[1] Efficacy and Safety Results of Guselkumab, an Anti-IL23 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis over 24 Weeks: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study
Deodhar, Atul A.
Gottlieb, Alice B.
Boehncke, Wolf-Henning
Dong, Bin
Wang, Yuhua
Barchuk, William
Xu, Xie
Hsia, Elizabeth C.
ARTHRITIS & RHEUMATOLOGY, 2016, 68
[2] EFFICACY AND SAFETY RESULTS OF GUSELKUMAB, AN ANTI-IL23 MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS OVER 24 WEEKS: A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Deodhar, A.
Gottlieb, A.
Boehncke, W. -H.
Dong, B.
Wang, Y.
Barchuk, W.
Xu, X. L.
Hsia, E.
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 142 - 143
[3] Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study
Deodhar, Atul
Gottlieb, Alice B.
Boehncke, Wolf-Henning
Dong, Bin
Wang, Yuhua
Zhuang, Yanli
Barchuk, William
Xu, Xie L.
Hsia, Elizabeth C.
LANCET, 2018, 391 (10136): : 2213 - 2224
[4] Efficacy and Safety Results of Guselkumab in Patients with Active Psoriatic Arthritis over 56 Weeks from a Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study
Deodhar, Atul A.
Gottlieb, Alice B.
Boehncke, Wolf-Henning
Dong, Bin
Wang, Yuhua
Zhuang, Yanli
Barchuk, William
Xu, Xie L.
Hsia, Elizabeth
ARTHRITIS & RHEUMATOLOGY, 2017, 69
[5] EFFICACY AND SAFETY RESULTS OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS OVER 56 WEEKS FROM A PHASE 2A, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Deodhar, A.
Gottlieb, A. B.
Boehricke, W-H.
Dong, B.
Wang, Y.
Zhuang, Y.
Barchuk, W.
Xu, X. L.
Hsia, E.
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 201 - 201
[6] EFFICACY AND SAFETY OF GUSELKUMAB IN BIOLOGIC-NAIVE PATIENTS WITH ACTIVE AXIAL PSORIATIC ARTHRITIS: STUDY DESIGN OF A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Gladman, D. D.
Mease, P. J.
Bird, P.
Soriano, E.
Chakravarty, S. D.
Shawi, M.
Xu, S.
Quinn, S.
Gong, C.
Leibowitz, E.
Tam, L. S.
Helliwell, P.
Kavanaugh, A.
Deodhar, A.
Ostergaard, M.
Baraliakos, X.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1574 - 1575
[7] GUSELKUMAB, AN ANTI-INTERLEUKIN-23P19 MONOCLONAL ANTIBODY, IN BIOLOGIC-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: WEEK 24 RESULTS OF THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Mease, Philip J.
Rahman, Proton
Gottlieb, Alice
Hsia, Elizabeth
Kollmeier, Alexa P.
Xu, Xie L.
Subramanian, Ramanand A.
Agarwal, Prasheen
Sheng, Shihong
Zhou, Bei
van der Helide, Desiree
Zazzetti, Federico
McInnes, Lin B.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 23 - 23
[8] Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Biologic-naive Patients with Active Psoriatic Arthritis: Week 24 Results of the Phase 3, Randomized, Double-blind, Placebo-controlled Study
Mease, Philip J.
Rahman, Proton
Gottlieb, Alice B.
Hsia, Elizabeth
Kollmeier, Alexa
Xu, Xie
Subramanian, Ramanand
Agarwal, Prasheen
Sheng, Shihong
Zhou, Bei
van der Heijde, Desiree
McInnes, Iain
ARTHRITIS & RHEUMATOLOGY, 2019, 71
[9] A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study of Tildrakizumab Efficacy and Safety in Patients With Active Ankylosing Spondylitis
Peters, Eric
Chou, Richard C.
Rozzo, Stephen J.
Yao, Siu-Long
Fructuoso, Ferran Jose Garcia
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2023, 29 (05) : 223 - 229
[10] Vunakizumab in Patients with Active Psoriatic Arthritis: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study
Zou, Hejian
Wan, Weiguo
Xue, Yu
Sun, Lingyun
Zhang, Ning
Chen, Haiying
Shi, Xiaofei
Liu, Shengyun
Chen, Lin
Ma, Xinmei
Wei, Hua
Jiang, Zhenyu
Li, Xiaomei
Fan, Hongtao
Li, Hongbin
Li, Jingyang
Wu, Rui
Shi, Guixiu
Zhu, Jing
Kong, Xiaodan
Lu, Yuewu
Cui, Xiaojing
Zheng, Qianning
Bai, Xiaoyan
Dong, Guangchao
ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 5240 - 5242

← 1 2 3 4 5 →